Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 28, 2007 Brian Lawler	Bioenvision Shareholder Battle Genzyme announces that it "cannot and will not" raise its $5.60-a-share bid for Bioenvision before shareholders go to vote on its proposed takeover. Investors, take note.
The Motley Fool February 20, 2007 Dan Caplinger	Get Out and Vote! Proxy voting lets your shareholder voice be heard.
The Motley Fool May 5, 2006 Selena Maranjian	Think Twice Before Agreeing With Management Did you know that companies in which you own stock may be doing things you don't like, and you may be giving them your blessing? Investors, proxy voting probably doesn't work the way you think it does.
BusinessWeek March 22, 2004 Gene G. Marcial	Look Who May Be Courting Bioenvision Genzyme may be interested in Bioenvision as well. Why? In 2001, Bioenvision licensed to ILEX the right to co-develop and market in the U.S. and Canada its Clorfarabine, a drug for leukemia. Bioenvision still holds the rights outside North America. The company will soon file for Food & Drug Administration approval of Clorfarabine, which has a $1 billion market potential.
BusinessWeek June 4, 2007 Gene G. Marcial	What Big Investors See In Bioenvision Bioenvision has attracted big investors.
The Motley Fool October 11, 2004 Tim Beyers	Don't Waste Your Vote Every year, as a shareholder, you're given the chance to have a say in how the companies you own are run. Don't blow it. Vote.
The Motley Fool January 9, 2008 Brian Lawler	Tracking Genzyme The biopharma updates investors on what to expect for 2008.
The Motley Fool May 14, 2004 Selena Maranjian	Shareholders Take Action Here are some tips on how to make a difference with your holdings.
The Motley Fool January 24, 2006 S.J. Caplan	Read Those Proxy Statements in 2006 Shareholder resolutions are an increasingly important vehicle for shareholder activism of all sorts.
The Motley Fool June 15, 2010 Ryan McBride	Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week.
The Motley Fool October 29, 2007 Brian Lawler	Genzyme Gets It Together Genzyme may not engender as much investor excitement as Carl-Icahn-acquisition-hyped biopharmas. But its diverse pipeline, and the strong performance it delivers quarter after quarter, deserve some investor attention.
The Motley Fool November 12, 2007 Selena Maranjian	Shareholders Are Winning ... Slowly CEO overcompensation is gradually being challenged in corporate America by shareholders, through resolutions and annual meeting proposals.
The Motley Fool August 10, 2009 Selena Maranjian	Shareholders Are Forcing Change You're not as powerless as you might think when it comes to important social issues.
The Motley Fool June 16, 2010 Alyce Lomax	Majority Rules! Majority voting standards would let shareholders have their say.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool February 27, 2009 Selena Maranjian	Voting: Not Just for November Anymore It's a very exciting time of year for investors: tax season, annual report season, and proxy voting season. Believe it or not, it's worth your time to sift through the mail and uncover your ballot; your proxy votes carry more power than you think.
The Motley Fool April 5, 2010 Jeffrey Morgan	Corporate America Wants Your Vote Why we should all care about corporate governance.
The Motley Fool May 30, 2007 Brian Lawler	Genzyme Gobbles Up a Partner Another day, another biotech acquisition for drugmaker Genzyme. Investors, with more than $500 million in free cash flow last year alone, Genzyme has money to spare.
U.S. Banker May 2007 Karen Krebsbach	Executive Pay, Still in the Hot Seat Shareholders are trying to gain more influence on executive pay as more resolutions hit the agenda at firms' annual meetings. But passage is proving to be tough.
The Motley Fool October 27, 2010 Selena Maranjian	When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders.
BusinessWeek May 2, 2005 Gene G. Marcial	What Other Biotechs See In Bioenvision Bioenvision's childhood leukemia drug Clofarabine has received FDA approval and is expected to increase the profitability of the drug maker.
The Motley Fool September 6, 2006 Brian Lawler	AnorMED's Tumultuous Year A takeover attempt follows management shakeups at the biopharmaceutical firm. Investors, take note.
The Motley Fool May 2, 2005 Jim Mueller	Sportsman's Guide's Red Flag How many stock options is the outdoor gear seller giving out? And it wants more? Here's an investor's red flag.
The Motley Fool September 17, 2007 Selena Maranjian	The SEC May Shut You Up If you want to keep the right to influence your companies, let the SEC know. The SEC has recently proposed changing rules for shareholders -- in ways that don't seem to protect them at all.
The Motley Fool January 11, 2008 Alyce Lomax	Whole Foods Joins the Moral Majority Whole Foods, the organic grocer, has amended its bylaws to adopt a majority voting standard for its director elections.
The Motley Fool June 16, 2010 Ryan McBride	Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors.
The Motley Fool July 22, 2011 Alyce Lomax	Shareholder Majorities Win Major Victories Policies that encourage better boards have gained traction in 2011.
BusinessWeek November 17, 2003 David Henry	Mutual Funds: Tossing Out The Rubber Stamp A new SEC rule that takes effect next year will require mutual funds to disclose how they vote on proxies for the stocks they own. The rule is intended to keep funds from siding with management to gain 401(k) business. How will this affect corporate governance?
Investment Advisor November 18, 2010 Mark Tibergien	The Right to Vote Debate about how to grow an advisory business becomes especially fervent when firm ownership broadens beyond the founder. Should ownership include the right to vote on policies, procedures and people?
The Motley Fool June 18, 2010 Yochim & Moscovitz	Don't Let Washington Kill Shareholder Rights Eleventh-hour backroom deals are unacceptable.
The Motley Fool April 3, 2006 Alyce Lomax	Your Stocks' Secrets Investors, knowledge is power, so don't ignore a freely available source of the best-kept corporate secrets -- the proxy statement. Proxy season is upon us -- don't forget to do your homework.
BusinessWeek December 6, 2004 Gene G. Marcial	Why There's New Life At Bioenvision Bioenvision's leading product, Clofarabine, for treating leukemia in children, may get Food & Drug Administration approval soon. Is the stock a good buy?
Salon.com October 10, 2000 Janelle Brown	Microsoft's funny money A spunky shareholder resolution demands that the company account for its political campaign contributions...
BusinessWeek January 31, 2005 Louis Lavelle	A Simple Way To Make Boards Behave Requiring directors to win a majority of votes would give shareholders more say. Investors at as many as 100 companies will vote on nonbinding shareholder resolutions urging those companies to adopt majority voting.
The Motley Fool September 14, 2007 Selena Maranjian	Shareholders Flexing Their Biceps The arena of proxy voting is not only interesting, it's also important. When you receive proxy-voting materials, take time to read through them and then cast your vote.
The Motley Fool March 26, 2010 Alyce Lomax	A Pivotal Proxy Season With shareholders more awake and aware than they've been in years, the latest proxy season could begin to fundamentally change managers' attitudes.
The Motley Fool June 10, 2010 Brian Orelli	Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday.
The Motley Fool July 8, 2009 Toby Shute	Shareholders 1, Board Bozos 0 Score one for shareholder empowerment.
The Motley Fool May 26, 2010 Brian Orelli	Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme.
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.
The Motley Fool November 18, 2010 Brian Orelli	Genzyme: Slimmed Down, Gussied Up But will anyone buy it?
U.S. Banker July 2004 John Adams	Institutional Custody: Union Bank Corrals E-Ballot Functionality Calls for transparency and more responsible mutual fund investing fuel demand for on-line proxy voting. With technology support, the public gets what it asks for.
The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool August 30, 2010 Ryan McBride	Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams.
Foundation News & Commentary Nov/Dec 2005 William F. McCalpin	Stewardship, Sustainability and Strength Developing proxy voting guidelines at the Rockefeller Brothers Fund became a priority. Here's how and why.
The Motley Fool July 12, 2006 Brian Lawler	Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share.
Financial Advisor January 2006 Joel Bruckenstein	Proxy Problems Simplified The Web-based PROXY Governance platform is a a technological solution for financial advisors' proxy-voting woes.
BusinessWeek February 9, 2004 Gene G. Marcial	Envisioning A Buyout For Bioenvision What's George Soros buying? In biotech, he has accumulated 27% of Bioenvision, a little-known biopharma. Other investors: OrbiMed Advisors, with 8%, and Deutsche Bank, with nearly 5%.